This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-utility analysis
Study objective
The objective of the study was to examine the cost-effectiveness of alternative strategies of population-level screening against breast cancer in Slovenia. The screening modalities varied depending on screening interval and age eligibility criteria.
Interventions
A total of 36 different screening mammography policies were considered with respect to the following eligibility criteria: age at the beginning of screening, age at the end of screening, and the interval between two screenings. All possible combinations of starting ages 40, 45 and 55 years, ending ages 65, 70, 75 and 80 years, and screening intervals of 1, 2 and 3 years were considered. The screening strategies were compared against a baseline option of no-screening.
Location/setting
Slovenia/primary care.
Methods

Analytical approach:
This economic evaluation was based on a time-dependent Markov model that simulated the natural course of breast cancer and the impact of alternative screening strategies on the costs and benefits. A lifetime horizon was chosen. The authors stated that the perspective of the health care sector was adopted.
Effectiveness data:
The epidemiological data (incidence and mortality rates) and clinical data (transition probabilities) used in the economic model were derived from the Cancer Registry of Slovenia. The authors also made some assumptions that were supported by published studies. For example, the duration of the so-called sojourn time (i.e. the period when the cancer is screen-detectable but shows no clinical symptoms) and the accuracy of screening were defined on the basis of some published reports. Screening attendance and recall rates were based on studies conducted in other countries, given the lack of Slovenian data.
Monetary benefit and utility valuations:
Quality-of-life estimates were based on published studies. The utility weights were provided, but details of the sources of these values were not given. The summary benefit measure was the quality-adjusted life-years (QALYs). These were estimated using the decision model. An annual discount rate of 3% was applied.
Measure of benefit:
Cost data:
The health services included in the analysis were the costs of a mammography examination, diagnostic interventions for clinically detected breast cancer, invasive and noninvasive diagnostic recall, and treatment interventions. These costs were derived from the Institute of Oncology Ljubljana. Treatment patterns used to calculate the costs of therapies were derived from the Cancer Registry of Slovenia. Long-term costs were discounted at an annual rate of 3%. The costs were in euros (EUR). The price year was 2004.
Analysis of uncertainty:
A deterministic univariate sensitivity analysis was performed in order to assess the robustness of the model results to variations in the clinical and economic inputs. A probabilistic sensitivity analysis was undertaken, with probabilistic distributions assigned to model inputs in order to generate cost-effectiveness acceptability curves and a costeffectiveness acceptability frontier. All model inputs were varied except breast cancer incidence and cost of mammography examination, which were, respectively, constant in recent years and fixed.
Results
Extensive results for costs, QALYs and cost-utility ratios were presented as supplementary material on the journal's website.
The incremental analysis showed that screening from ages 50 to 65 years every 3 years had the lowest cost per QALY gained over no screening. The strategies on the cost-effectiveness frontier were screening every 3 years from age 50 to 65 years, from age 40 to 70 years, from age 40 to 75 years, from age 40 to 80 years, from age 45 to 65 years and age 45 to 70 years, and screening every 2 years from age 40 to 80 years.
The probabilistic analysis, which used cost-effectiveness acceptability curves, showed that using the commonly quoted threshold of EUR 38,500 per QALY, the optimal strategy would be screening women aged from 40 to 80 years every 3 years. Screening women aged from 40 to 80 years every 2 years was the preferred option for a threshold higher than EUR 41,815 per QALY. The analysis also suggested that, in general, strategies of annual screening were not costeffective, owing to the increased costs and decreased benefits of false positives.
The one-way sensitivity analysis showed that the most influential model inputs were discount rate, rate of progression from ductal carcinoma in situ to invasive cancer, recall rate, relative mortality in regional stage, rate of invasive diagnostics and cost of mammography.
